{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:57:06Z","timestamp":1783947426861,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008884","name":"Edward P Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.leukres.2025.107693","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T06:37:30Z","timestamp":1744439850000},"page":"107693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-3107","authenticated-orcid":false,"given":"Brandon J.","family":"Aubrey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1346-988X","authenticated-orcid":false,"given":"Traci","family":"Blonquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1327-0948","authenticated-orcid":false,"given":"Malgorzata","family":"McMasters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-9333","authenticated-orcid":false,"given":"Gabriela","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"McAfee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacalyn","family":"Rosenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7770-2623","authenticated-orcid":false,"given":"Philip","family":"Amrein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aura","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimalangshu","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Avigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ballen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej","family":"El-Jawahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5848-6221","authenticated-orcid":false,"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2169-4115","authenticated-orcid":false,"given":"Andrew M.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2025.107693_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.leukres.2025.107693_bib2","first-page":"483 e481","article-title":"Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transpl. Cell Ther."},{"key":"10.1016\/j.leukres.2025.107693_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107693_bib4","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","article-title":"How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT","volume":"4","author":"Penack","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2025.107693_bib5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3324\/haematol.2015.123331","article-title":"Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT","volume":"100","author":"Sengsayadeth","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2025.107693_bib6","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.bbmt.2013.06.008","article-title":"Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies","volume":"19","author":"Brunner","year":"2013","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.leukres.2025.107693_bib7","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/bmt.2016.167","article-title":"Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2025.107693_bib8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.leukres.2025.107693_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.leukres.2025.107693_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS","volume":"523","author":"Kronke","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2025.107693_bib11","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.38430","article-title":"Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome","volume":"7","author":"Donovan","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.leukres.2025.107693_bib12","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1056\/NEJMcibr1811318","article-title":"Inhibition of casein kinase 1 alpha in acute myeloid Leukemia","volume":"379","author":"Ebert","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2025.107693_bib13","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3389\/fimmu.2018.00977","article-title":"Immunomodulatory drugs exert anti-leukemia effects in acute myeloid leukemia by direct and immunostimulatory activities","volume":"9","author":"Le Roy","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.leukres.2025.107693_bib14","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm.4127","article-title":"A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes","volume":"22","author":"Fang","year":"2016","journal-title":"Nat. Med"},{"key":"10.1016\/j.leukres.2025.107693_bib15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s43018-022-00366-1","article-title":"IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia","volume":"3","author":"Aubrey","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.leukres.2025.107693_bib16","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood.2023021105","article-title":"Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML","volume":"143","author":"Bourgeois","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107693_bib17","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.2147\/CMAR.S168610","article-title":"Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis","volume":"10","author":"Xie","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.leukres.2025.107693_bib18","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1200\/JCO.2010.30.3339","article-title":"Dose escalation of lenalidomide in relapsed or refractory acute leukemias","volume":"28","author":"Blum","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107693_bib19","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood.2020008735","article-title":"How I treat frontline transplantation-eligible multiple myeloma","volume":"139","author":"Perrot","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107693_bib20","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2025.107693_bib21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.leukres.2009.09.020","article-title":"Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status","volume":"34","author":"Matondo","year":"2010","journal-title":"Leuk. Res"},{"key":"10.1016\/j.leukres.2025.107693_bib22","doi-asserted-by":"crossref","first-page":"16220","DOI":"10.1073\/pnas.252462599","article-title":"Preferential induction of apoptosis for primary human leukemic stem cells","volume":"99","author":"Guzman","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.leukres.2025.107693_bib23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3324\/haematol.11666","article-title":"The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+\u2009immature phenotype","volume":"93","author":"Colado","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2025.107693_bib24","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1182\/blood.V98.8.2301","article-title":"Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells","volume":"98","author":"Guzman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107693_bib25","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.leukres.2013.05.011","article-title":"Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)","volume":"37","author":"Attar","year":"2013","journal-title":"Leuk. Res"},{"key":"10.1016\/j.leukres.2025.107693_bib26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood-2011-02-337303","article-title":"A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605","volume":"118","author":"Sekeres","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107693_bib27","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00277-020-04321-x","article-title":"Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group","volume":"100","author":"Schuler","year":"2021","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2025.107693_bib28","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.leukres.2025.107693_bib29","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107693_bib30","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/s41375-022-01537-w","article-title":"Randomized phase II study of azacitidine +\u2009\/- lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)","volume":"36","author":"Rasmussen","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107693_bib31","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/bjh.14407","article-title":"A phase 2 trial of high dose lenalidomide in patients with relapsed\/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia","volume":"176","author":"Zeidan","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2025.107693_bib32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clml.2012.04.001","article-title":"A phase II study of lenalidomide alone in relapsed\/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities","volume":"12","author":"Chen","year":"2012","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2025.107693_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28946","article-title":"Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia","volume":"68","author":"O'Brien","year":"2021","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.leukres.2025.107693_bib34","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107693_bib35","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.3324\/haematol.2012.067629","article-title":"Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial","volume":"97","author":"Sockel","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2025.107693_bib36","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/JCO.18.00889","article-title":"Combination lenalidomide and azacitidine: a novel salvage therapy in patients who relapse after allogeneic stem-cell transplantation for acute myeloid leukemia","volume":"37","author":"Craddock","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107693_bib37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clml.2019.09.615","article-title":"Lenalidomide plus hypomethylating agent as a treatment option in acute myeloid leukemia with recurrent genetic abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM","volume":"20","author":"Merz","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2025.107693_bib38","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3324\/haematol.2012.076414","article-title":"Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia","volume":"98","author":"Pollyea","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.leukres.2025.107693_bib39","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1080\/16078454.2019.1631425","article-title":"A systematic review and meta-analysis of the efficacy and adverse events of azacitidine-plus-lenalidomide treatment for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"24","author":"Kunacheewa","year":"2019","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2025.107693_bib40","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107693_bib41","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3324\/haematol.2016.151894","article-title":"Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myelodysplasies","volume":"102","author":"Ades","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2025.107693_bib42","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/ajh.25958","article-title":"A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"95","author":"Saygin","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2025.107693_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/bjh.13281","article-title":"Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia","volume":"169","author":"Wei","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2025.107693_bib44","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/cncr.33409","article-title":"Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission","volume":"127","author":"Abou Dalle","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2025.107693_bib45","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1038\/s41409-021-01444-1","article-title":"Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"56","author":"Pham","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2025.107693_bib46","article-title":"Phase II study of bortezomib as a single agent in patients with previously untreated or relapsed\/refractory acute myeloid leukemia ineligible for intensive therapy","volume":"2013","author":"Sarlo","year":"2013","journal-title":"Leuk. Res Treat."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T09:27:18Z","timestamp":1746610038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625000530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":46,"alternative-id":["S0145212625000530"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107693","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107693"}}